Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Isotope Labelled Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade |
---|---|
Source | DrugBank DB00112 |
Species | Human |
Expression system | Mammalian cells |
Molecular weight | 149kDa |
Purity | >95% |
Buffer | PBS pH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | 4°C for short term; -20°C for long term |
Brand | ProteoGenix |
Applications | MS |
Aliases /Synonyms | Bevacizumab |
Reference | PX-TA1006-SIL |
Related Products | PX-P1167 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1 |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
Formula | C6538H10034N1716O2033S44 |
Bevacizumab, is classified as a monoclonal antibody and/or anti-angiogenesis drug. It is a comparatively new type of cancer therapy. Antibodies are an essential part of the immune system. The body creates antibodies in response to an antigen entering the body. These antibodies attach themselves to the antigen, to mark it for destruction by the bodys immune system. Bevacizumab allows human body to target specific cells, causing less toxicity to healthy cells. It works by interfering with the process of angiogenesis by targeting and inhibiting human vascular endothelial growth factor (VEGF). VEGF is a cytokine (a small protein released by cells that have specific effects on the behavior of cells) which when it interacts with its receptors in the cell leads to new blood vessel formation or angiogenesis. This product is for research use only.
Reviews
Il n’y a pas encore d’avis.